2- (N- (4- chlorophenyl)- N- methylamino)- 4H- pyrido(3,2- e)- 1,3- thiazin- 4- one

08/01/2004 - "injection of YM928 at 5 mg/kg or 10 mg/kg significantly increased the number of stimulations required to elicit generalized seizure. "
06/28/2004 - "YM928 (10 and 30 mg/kg p.o.) markedly suppressed the motor seizures and afterdischarge induced by electrical stimulation of the amygdala at generalized seizure-triggering threshold intensity. "
01/01/2004 - "These results indicate that YM928 is a broad-spectrum anticonvulsant that would prove useful for the treatment of generalized seizure in human epileptic patients."
01/01/2019 - "The protective index values of 25 and 27 for MES-induced seizures (10.7 and 12.0, respectively) and PTZ-induced seizures (6.0 and 5.6, respectively) were considerably higher compared with those of YM928 (5) and talampanel (1)."
08/01/2004 - "These results indicate that YM928 has anticonvulsant effects on seizure models that are characteristic of partial onset seizures in humans. "

07/01/2003 - "In terms of in vivo activity, YM928 had an anticonvulsant effect in sound-induced seizures in DBA/2 mice 45 min after oral administration at 3 mg/kg. Thus, YM928 has potential as an oral therapeutic drug for various types of neurological disorders."

08/01/2004 - "YM928 is expected to have beneficial effects against human complex partial seizure with secondary generalization or temporal lobe epilepsy."

06/28/2004 - "Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy."